Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-03-04
DOI
10.1200/jco.21.01806
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
- (2020) Esther Lutgens et al. Journal for ImmunoTherapy of Cancer
- Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer—a meta‐analysis
- (2020) Lars Michel et al. ESC Heart Failure
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
- (2020) Viktor Grünwald et al. BRITISH JOURNAL OF CANCER
- Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology
- (2020) Radek Pudil et al. EUROPEAN JOURNAL OF HEART FAILURE
- Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience
- (2019) Katherine Lee Chuy et al. ONCOLOGIST
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular toxicities associated with immune checkpoint inhibitors
- (2019) Jiun-Ruey Hu et al. CARDIOVASCULAR RESEARCH
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Myocarditis in the Setting of Cancer Therapeutics
- (2019) Marc P. Bonaca et al. CIRCULATION
- A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies
- (2019) Christina W. Guo et al. EUROPEAN JOURNAL OF CANCER
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events
- (2018) Rhian M. Touyz et al. Journal of the American Society of Hypertension
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- The Role of Biomarkers in Detection of Cardio-toxicity
- (2017) Kevin S. Shah et al. Current Oncology Reports
- Cardiovascular Toxicities Associated with Cancer Immunotherapies
- (2017) Daniel Y. Wang et al. Current Cardiology Reports
- Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?
- (2016) Anne-Sophie Bargnoux et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Cardiovascular Toxic Effects of Targeted Cancer Therapies
- (2016) Javid J. Moslehi NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
- (2015) N. B. Haas et al. CLINICAL CANCER RESEARCH
- Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction
- (2014) M. Rubini Gimenez et al. EUROPEAN HEART JOURNAL
- Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
- (2013) Steven M. Bair et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC)
- (2013) Ruth F Dubin et al. BMC Nephrology
- Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays
- (2011) F. S. Apple et al. CLINICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now